The performance of companies tied to Viagra's past presents a complex investment scenario . While the initial success generated substantial profits , generic competition have significantly diminished revenue. Investing in connected pharmaceutical businesses now requires a discerning assessment of patent rights , evolving medical shifts , and the pr